Bioscience Valuation
Thomas Loeser has extensive experience in financial leadership and advisory roles within the healthcare and biopharmaceutical sectors. Currently serving as Managing Partner at Viopas Venture Consulting GmbH, Thomas Loeser focuses on providing tailored services to healthcare companies and investors. As a Senior Financial Advisor at Bioscience Valuation since November 2019, expertise lies in analyzing financial and life sciences intersections. Previous positions include Chief Financial Officer at T-CURX GmbH, CFO at Origenis GmbH, and Interim CFO at eADMET GmbH. Thomas Loeser also founded TL Asset & Interim Management, specializing in asset management for biotech companies. Early career achievements include critical roles at ESBATech and Morphochem AG, where significant fundraising and company expansions were accomplished. Educational background includes studies in economics at Ludwig-Maximilians-Universität München and completion of the Advanced Management Program at Harvard Business School.
This person is not in any teams
Bioscience Valuation
Bioscience Valuation (BSV) is a globally operating boutique life sciences consulting company. We serve all private and public entities involved in the life sciences – including biotech and pharma companies, investment funds, and research organizations. At the time of our inception, we were pioneers in our field. Foundational papers authored by our co-founders now form the cornerstone of valuation methods taught at the world’s leading business schools. Today, we’ve evolved into a full-grown service provider addressing the needs of all organizations active in the life sciences. We are headquartered in the Munich Metropolitan Region and serve clients on all continents. Please don't hesitate to reach out!